Linked Life Data

21053357

Source:http://linkedlifedata.com/resource/pubmed/id/21053357

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-6-15
pubmed:abstractText
The United States spends more for healthcare than any other country in the world. With the rising prevalence of both Crohn's disease and ulcerative colitis, inflammatory bowel disease (IBD) represents the leading chronic gastrointestinal disease with increasing healthcare expenditures in the US. IBD costs have shifted from inpatient to outpatient care since the introduction of biologic therapies as the standard of care. Gastroenterologists need to be aware of the national cost burden of IBD and clinical practices that optimize cost-efficiency. This investigation offers a systematic review of the economics of IBD and evidence-based strategies for cost-effective management.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1536-4844
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
pubmed:issnType
Electronic
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1603-9
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.
pubmed:affiliation
Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children's Hospital, Stanford University Medical Center, Stanford, California, CA, USA. ktpark@stanford.edu
pubmed:publicationType
Journal Article, Review